TY - JOUR
T1 - Synthetic nanovaccines for immunotherapy
AU - Luo, Min
AU - Samandi, Layla Z.
AU - Wang, Zhaohui
AU - Chen, Zhijian J.
AU - Gao, Jinming
N1 - Publisher Copyright:
© 2017 Elsevier B.V.
PY - 2017/10/10
Y1 - 2017/10/10
N2 - Although vaccination is historically one of the most successful strategies for the prevention of infectious diseases, development of vaccines for cancer and many chronic infections, such as HIV, malaria, and tuberculosis, has remained a challenge. Strong and long-lasting antigen-specific T cell responses are critical for therapy of these diseases. A major challenge in achieving a robust CD8 + T cell response is the requirement of spatio-temporal orchestration of antigen cross-presentation in antigen-presenting cells with innate stimulation. Here, we discuss the development of nanoparticle vaccine (nanovaccine) that modulates the innate immune system and enhances adaptive immunity with reduced toxicity. We address how nanovaccines can integrate multiple functions, such as lymph node targeting, antigen presentation, and stimulation of innate immunity, to achieve a robust T cell response for immunotherapy.
AB - Although vaccination is historically one of the most successful strategies for the prevention of infectious diseases, development of vaccines for cancer and many chronic infections, such as HIV, malaria, and tuberculosis, has remained a challenge. Strong and long-lasting antigen-specific T cell responses are critical for therapy of these diseases. A major challenge in achieving a robust CD8 + T cell response is the requirement of spatio-temporal orchestration of antigen cross-presentation in antigen-presenting cells with innate stimulation. Here, we discuss the development of nanoparticle vaccine (nanovaccine) that modulates the innate immune system and enhances adaptive immunity with reduced toxicity. We address how nanovaccines can integrate multiple functions, such as lymph node targeting, antigen presentation, and stimulation of innate immunity, to achieve a robust T cell response for immunotherapy.
KW - Immunotherapy
KW - Nanovaccine
KW - Synthetic nanoparticle
KW - T cell response
UR - http://www.scopus.com/inward/record.url?scp=85018241827&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85018241827&partnerID=8YFLogxK
U2 - 10.1016/j.jconrel.2017.03.033
DO - 10.1016/j.jconrel.2017.03.033
M3 - Article
C2 - 28336379
AN - SCOPUS:85018241827
SN - 0168-3659
VL - 263
SP - 200
EP - 210
JO - Journal of Controlled Release
JF - Journal of Controlled Release
ER -